SynOx Therapeutics, a Dublin, Ireland and Oxford, UK-based late-stage clinical biopharmaceutical company, closed a $75m Series B financing.
The round was co-led by Forbion, HealthCap and new investor Bioqube Ventures. As part of the Series B financing both Forbion Dr Carlo Incerti, M.D., and Bioqube Ventures Jon Edwards, PhD, have joined the Board of Directors.
The company intends to use the funds to generate registrational Phase 3 clinical and CMC data for emactuzumab, its potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of Tenosynovial Giant Cell Tumour (TGCT).
Led by Ray Barlow, Chief Executive Officer, SynOx Therapeutics is a clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders.
Emactuzumab is a novel, next-generation CSF-1R mAb with a potentially best-in-class profile. In earlier clinical work in TGCT emactuzumab demonstrated substantial clinical activity with an objective response rate (ORR) of 71%, rapid and robust tumour reduction, a long duration of effect, and significant improvements in functional ability. Importantly, these studies also indicated that emactuzumab has good tolerability and a manageable safety profile. SynOx is initiating a Phase 3 trial (TANGENT) to assess the efficacy and safety of emactuzumab in patients with localized and diffuse TGCT.
FinSMEs
22/04/2024